NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP
SkinHealth Systems Inc. SKIN
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$300.8M
▼ 10.0% vs FY2024
EPS · FY25
$-0.16
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-16.9%
Net margin · FY25
-3.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 300.8M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 3 cents on every revenue dollar this year.
Per share
USD -0.16
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.9%
Return on equity, FY2025
ROE
Operating margin-6.9%
Net margin-3.2%
Return on assets-1.6%
Each USD of equity lost 17 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 0.00
Share of profit-0.0%
Consecutive raises—
Growth
+20.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−6.3%
+20.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 499.8M
total assets, end of FY2025
Total assetsUSD 499.8M
EquityUSD 61.1M
CashUSD 232.7M
Current ratio1.66×
Equity funds 12% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.3
0.3
0.4
0.4
0.3
0.1
0.2
Operating income $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.1
0.0
−0.4
−0.0
−0.0
EPS, diluted $
−0.16
−0.36
−0.76
−0.23
−3.71
−0.85
−0.05
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−16.9
−52.3
−88.4
19.0
−283.2
·
·
Shares out B
0.13
0.12
0.12
0.13
0.13
0.04
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed